Amgen, Teva Settle Patent Suit Over Neopogen Generic
U.S. District Judge Stewart Dalzell's order held that Amgen's patents covering the use of human granulocyte colony-stimulating factor were valid and enforceable. Further, Teva is banned from marketing or selling its Neopogen generic until November 2013, according to the judge's decision.
The terms of the settlement, which were agreed upon earlier...
To view the full article, register now.